| Document |
Document Title |
|
WO/2022/054795A1 |
The present invention provides an immunogenic composition comprising an antigenic peptide, which is capable of inducing the production of an antibody against a phosphorylated tau protein, and a carrier protein, wherein the antigenic pept...
|
|
WO/2022/052958A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/055334A1 |
The present invention relates to a novel use of granulocyte colony-stimulating factor, also known as colony-stimulating factor 3 (CSF3) as an anticancer adjuvant comprising an inhibitor of CSF3 or as a biomarker and therapeutic target fo...
|
|
WO/2022/050230A1 |
A composition for inhibiting the production of IL-22, IL-31 or IFN-kappa, or for treating, ameliorating or preventing diseases caused by abnormal production of IL-22, IL-31 or IFN-kappa, said composition comprising, as an active ingredie...
|
|
WO/2022/049814A1 |
The present invention addresses the problem of providing a substance that inhibits the growth of herpes simplex virus (HSV) in cells and also providing a medicine or a medicinal composition for treating acute retinal necrosis that compri...
|
|
WO/2022/050295A1 |
Provided is a composition for external use on skin, which can be packed in a container easily in the production thereof and is configured such that a proper amount can be discharged upon the application onto the skin. A composition for...
|
|
WO/2022/049168A1 |
The present invention relates to the use of 17(S)-HDPA against metabolic syndrome related diseases including NAFLD/NASH.
|
|
WO/2022/050355A1 |
There is a problem that the effect of known seretonin transporter (SERT) inhibitors (SSRI) on diseases involving SERT (e.g., depression, obsessive-compulsive disorder (OCD), schizophrenia, and Alzheimer's dementia) is limited. In the pre...
|
|
WO/2022/050173A1 |
This surface-treated hydrotalcite is obtained by surface-treating a hydrotalcite having a compositional makeup represented by formula (1) and satisfies (A)-(C). This hydrotalcite has excellent dispersibility. (Wherein, respective signs i...
|
|
WO/2022/050373A1 |
The present invention addresses the problem of providing: a purified concentrate of a culture supernatant, which has high effectiveness and high safety; and a method for producing the purified concentrate. According to the present invent...
|
|
WO/2022/050385A1 |
A compound represented by formula (2): [in the formula, R1 represents a hydrogen atom, etc., R2 represents a methoxy group, etc., R3 represents a hydrogen atom, etc., R4 represents an optionally substituted C1-6 alkyl group, etc., m repr...
|
|
WO/2022/047548A1 |
This invention relates to solid forms of 1-methyl-1,4,5,10-tetrahydropyrazolo[3,4-b][1,5]benzodiazepi
ne freebase possessing desirable pharmacokinetic properties, such as low hygroscopicity and improved thermal stability. These solid for...
|
|
WO/2022/050308A1 |
The present disclosure addresses the problem of providing at least a technique for enhancing the expression of NAMPT gene. This problem is solved by a composition for enhancing NAMPT gene expression, said composition comprising an equol ...
|
|
WO/2022/050318A1 |
To provide a new method for using placenta extract for a clearer purpose than in the past. The use of placenta extract as an additive material for any component selected from components that suppress or promote melanin production, comp...
|
|
WO/2022/048685A1 |
Disclosed are a crystal form of benzotetrahydrofuran oxime compound and a preparation method therefor. Further disclosed is the use of the crystal form in the preparation of a drug for treating related diseases.
|
|
WO/2022/045183A1 |
The present invention pertains to a prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis, in particular, a prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF, etc.) that comprises a compou...
|
|
WO/2022/045052A1 |
Provided is a compound represented by formula (1) or a salt thereof.
|
|
WO/2022/045261A1 |
The present invention addresses the problem of developing of a drug capable of inhibiting downregulation of a CD39 gene involved in activation of Langerhans cells and modulating an immune response of the skin. The invention is based on t...
|
|
WO/2022/046650A1 |
Described herein are pharmaceutical compositions containing compounds which inhibit the activity of Olig2 in combination with a second therapeutic agent. Also described herein are methods of using such pharmaceutical compositions for tre...
|
|
WO/2022/045091A1 |
Provided is a means that is useful for imparting kaempferol-induced physiological effects. A plant extract according to the present invention contains 1 mg/g or more of kaempferol aglycone in terms of dry weight.
|
|
WO/2022/045074A1 |
The present invention provides a pharmaceutical composition for preventing or treating obesity, said pharmaceutical composition enhancing the expression of at least one gene selected from the group consisting of NFIA, UCP-1, PPARγ, PGC1...
|
|
WO/2022/045336A1 |
The present disclosure provides a therapeutic agent useful for the treatment of motor fluctuations (e.g., wearing-off) in Parkinson's disease. In particular, the present disclosure provides: a composition characterized by containing tand...
|
|
WO/2022/045835A1 |
The present invention relates to a composition comprising an Atractylodes macrocephala and Agastache rugosa mixed extract for alleviating fatigue or enhancing exercise performance. The composition comprising an Atractylodes macrocephala ...
|
|
WO/2022/045093A1 |
The present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt.
|
|
WO/2022/043407A1 |
Disclosed are compositions comprising active ingredients selected from a list consisting of a terpene, a quinone, an organosulfur compound, and a vitamin. The compositions are intended for the treatment of neurological disorders, in part...
|
|
WO/2022/046873A1 |
The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of d...
|
|
WO/2022/044024A1 |
Compounds usable as substrate-competitive inhibitors of GSK-3, and uses thereof in modulating (e.g., inhibiting) GSK-3 activity and in treating biological conditions associated with GSK-3, are provided. The compounds can be collectively ...
|
|
WO/2022/043273A2 |
The present invention relates to an oral care composition comprising a fructanase, use of said composition as medicaments, use of said composition in treatment of oral disease, methods of treatment comprising administering said compositi...
|
|
WO/2022/045041A1 |
Disclosed is a thioredoxin interacting protein (TXNIP) expression inhibitor containing a curcumin derivative represented by formula (I) (In the formula, R1 are each independently a hydrogen atom, CH2F-, CHF2-, CF3-, CH2FO-, CHF2O-, or CF...
|
|
WO/2022/045200A1 |
Disclosed is a topical solution for hyperhidrosis treatment containing oxybutynin or a pharmaceutically acceptable salt thereof, water, and a lower alcohol, wherein the content of oxybutynin or pharmaceutically acceptable salt thereof in...
|
|
WO/2022/038490A1 |
The present disclosure provides pharmaceutical compositions comprising thiotepa, water, one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally thiosulfate. Also provided is a method for treating cancer in a subject, or...
|
|
WO/2022/040070A1 |
The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential tre...
|
|
WO/2022/039026A1 |
[Problem] To provide an artificial protein that can inhibit the function of Ras present in cancer cells and suppress cancer cell proliferation, and a Ras inhibitor and an anticancer agent using the artificial protein. [Solution] The arti...
|
|
WO/2022/038213A1 |
The invention concerns an alginate hydrogel or a new composition derived therefrom further comprising another calcium chelator such as sodium thiosulfate and/or calcium crystal solubilizer or inhibitor, and their use in the treatment of ...
|
|
WO/2022/039190A1 |
The objective of the present invention is to provide an inexpensive and effective sirtuin activating substance derived from a natural product. Said objective of the present invention can be achieved by: a sirtuin activator including β...
|
|
WO/2022/037481A1 |
Provided is an immunologically compatible and reversible universal pluripotent stem cell or a derivative thereof. An inducible gene expression system and the expression sequence of at least one immunologically compatible molecule are int...
|
|
WO/2022/040365A1 |
The present disclosure relates to a composition of a biologically pure isolate of the genus Salmonella comprising archival strain CRC1674, wherein the isolate further comprises a disruption of at least one gene selected from the group co...
|
|
WO/2022/039223A1 |
The present invention addresses the problem of providing a reversible opening agent for a nervous system vascular barrier. To solve the problem, a reversible opening agent for a nervous system vascular barrier is prepared, the reversib...
|
|
WO/2022/035969A1 |
Gadolinium based contrast agents (GCA) incorporating linear ligand chelation are fundamentally different from GCAs incorporating macrocyclic ligands. The macrocyclicN GCAs are synthesized by pathways characterized by the formation of a s...
|
|
WO/2022/034911A1 |
A composition for a leave-on-type skin external preparation, the composition comprising (A) at least one acid selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or a salt of the acid and (B) a nonionic surf...
|
|
WO/2022/034664A1 |
The present invention provides a pharmaceutical composition that is useful for preventing or treating bone diseases relating to abnormality in the balance of osteoclasts and osteoblasts, in particular, bone diseases associated with infla...
|
|
WO/2022/034912A1 |
The present invention provides an anti-human TRPV2 antibody, which recognizes an extracellular domain of human TRPV2 as an epitope, or a fragment thereof.
|
|
WO/2022/034833A1 |
Provided are an IL-8 inhibitor, an anti-aging agent for the skin, and a method for controlling skin aging that uses the same. Provided are an IL-8 inhibitor, an IL-8 translation inhibitor, and an anti-aging agent for skin that contain ...
|
|
WO/2022/035895A1 |
Provided herein are methods and compositions for expansion of human embryonic stem with suspendable expansion complexes including microcarriers.
|
|
WO/2022/035326A1 |
The invention relates to processing methods to produce Bee Product Extracts produced from a Bee Product such as honey, pollen, waxes, or royal jelly; and in particular a Bee Product Extract produced from purifying manuka honey with catio...
|
|
WO/2022/035220A1 |
The present invention relates to a composition for preventing, improving or treating muscle weakness-related muscle diseases, comprising a chestnut flower extract as an active ingredient. The composition is effective in the amelioration ...
|
|
WO/2022/036121A1 |
A composition and a method for improving mood, particularly reducing stress, anxiety and/or depression including administering a composition including at least two prebiotics selected from a source of pectin, a source of beta-glucan, a s...
|
|
WO/2022/033538A1 |
Provided is an antibody which can specifically recognize IL-11 or an antigen-binding fragment thereof. The antibody contains CDR sequence(s) selected from at least one of the following or an amino acid sequence having at least 95% identi...
|
|
WO/2022/029497A1 |
Disclosed is ularitide for use in methods for treating refractory ascites, comprising subcutaneously administering ularitide to a patient in need thereof via an implantable drug depot composition or via an infusion pump system, wherein t...
|
|
WO/2022/029070A1 |
The present invention relates to a compound and a pharmaceutical composition for use in the treatment and/or prophylaxis of a lipofuscin-associated disease and/or a disease associated with aged oxidized melanin of a living being. It also...
|
